Clinical trials: Recurrent Hodgkin Lymphoma
Relapsed or Refractory Peripheral T-Cell Lymphoma
Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy
Phase II study designed to investigate antitumor activity in terms of objective response rate (ORR) of tipifarnib subjects with advanced Peripheral T-Cell Lymphoma (PTCL).
- Trial name
- PTCL (NCT02464228)
- Testing
- Tipifarnib
- Where
- 13 sites in United States, South Korea and 1 more
- Volunteers
- 65 people
- Sponsor
- Kura Oncology, Inc.
Drug/Agent Toxicity by Tissue/Organ, Lymphoma
Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma
RATIONALE: Denileukin diftitox may be able to deliver cancer-killing substances directly to T-cell lymphoma cells. Dexamethasone may decrease the side effects of denileukin diftitox.
- Trial name
- NCT00006345
- Testing
- denileukin diftitox, dexamethasone
- Where
- 11 sites in United States
- Sponsor
- Ligand Pharmaceuticals
Lymphoma
A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)
The purpose of this study is to assess the safety and efficacy of parsaclisib in subjects with relapsed or refractory diffuse large B-cell lymphoma.
- Trial name
- NCT02998476
- Testing
- Parsaclisib
- Where
- 70 sites in United States, Australia and 9 more
- Volunteers
- 60 people
- Sponsor
- Incyte Corporation
Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia
The goal of this clinical trial is to learn if sonrotoclax (BGB-11417) is safe and may help treat children and adolescents with acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) that has come back after treatment…
- Conditions
- Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, Pediatric Cancer
- Trial name
- NCT07770698
- Testing
- sonrotoclax, Azacitidine, Inotuzumab ozogamicin
- Volunteers
- 30 people
- Sponsor
- BeOne Medicines
Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides
Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients
The purpose of this study is to compare the effectiveness of two dose levels of ONTAK (denileukin diftitox) in treating patients who have recurrent or persistent cutaneous T-cell lymphoma.
- Conditions
- Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides, Sezary Syndrome
- Trial name
- NCT00050999
- Testing
- ONTAK
- Where
- 35 sites in United States, Australia and 8 more
- Volunteers
- 195 people
- Sponsor
- Eisai Inc.
Lymphoma, Non-Hodgkin's
A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL)
This is a Phase III, multicenter, global, clinical study of an investigational drug called galiximab in combination with an approved drug called rituximab in subjects with follicular NHL.
- Trial name
- NCT00363636
- Testing
- Galiximab in combination with rituximab
- Volunteers
- 340 people
- Sponsor
- Biogen
Relapsed or Refractory Multiple Myeloma (RRMM), Diffuse Large B Cell Lymphoma (DLBCL)
GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies
The drug that will be investigated in the study is an antibody, GEN3014. Since this is the first study of GEN3014 in humans, the main purpose is to evaluate safety.
- Conditions
- Relapsed or Refractory Multiple Myeloma (RRMM), Diffuse Large B Cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML)
- Trial name
- NCT04824794
- Testing
- GEN3014, Daratumumab
- Where
- 52 sites in United States, Australia and 18 more
- Volunteers
- 130 people
- Sponsor
- Genmab
Lymphoma
Vaccine Therapy and GM-CSF in Treating Patients With Progressive Non-Hodgkin's Lymphoma
RATIONALE: Vaccines made from a person's cancer cells may make the body build an effective immune response to kill cancer cells.
- Trial name
- NCT00104819
- Testing
- autologous immunoglobulin idiotype-KLH conjugate vaccine, sargramostim
- Where
- 51 sites in United States
- Volunteers
- 238 people
- Sponsor
- Favrille
Classical Hodgkin Lymphoma, Hodgkin Disease Refractory
Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy
This is a Phase 1b, multicenter, open-label, single arm study to evaluate the safety and efficacy of the combination therapy, CD30.CAR-T and the programmed cell death protein-1 (PD-1) checkpoint inhibitor, nivolumab, in patients…
- Conditions
- Classical Hodgkin Lymphoma, Hodgkin Disease Refractory, Hodgkin Disease Recurrent
- Trial name
- ACTION (NCT05352828)
- Testing
- Nivolumab, Autologous CD30.CAR-T, Fludarabine
- Where
- 5 sites in United States
- Volunteers
- 15 people
- Sponsor
- Tessa Therapeutics
Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
A Study to Learn More About Copanlisib Treatment Patterns in People With Indolent Non-Hodgkin Lymphoma, a Type of Cancer That Grows and Spread Slowly and Develops in the Lymphatic System (a Part of Immune System) in Taiwan Under Real-word Conditions
This is an observational study, in which data from Taiwanese people with indolent non-Hodgkin lymphoma who will be receiving copanlisib is studied.
- Trial name
- NCT05217914
- Testing
- Copanlisib (BAY80-6946)
- Where
- Taiwan
- Volunteers
- 6 people
- Sponsor
- Bayer
Ependymoma, Ewing Sarcoma
A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer
The purpose of this study is to first, in Part A, assess the safety, tolerability and drug levels of Bempegaldesleukin (BEMPEG) in combination with nivolumab and then, in Part B, to estimate the preliminary efficacy in children…
- Conditions
- Ependymoma, Ewing Sarcoma, High-grade Glioma, Leukemia and Lymphoma
- Trial name
- PIVOT IO 020 (NCT04730349)
- Testing
- Nivolumab, NKTR-214
- Where
- 18 sites in United States, Australia and 4 more
- Volunteers
- 15 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Castration Resistant Prostate Cancer (mCRPC), Small Cell Lung Cancer (SCLC)
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
The purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate…
- Conditions
- Metastatic Castration Resistant Prostate Cancer (mCRPC), Small Cell Lung Cancer (SCLC), Follicular Lymphoma (FL)
- Trial name
- NCT03460977
- Testing
- Mevrometostat (PF-06821497), Enzalutamide, Itraconazole
- Where
- 85 sites in United States, Bulgaria and 6 more
- Volunteers
- 453 people
- Sponsor
- Pfizer
Lymphoma, Prostate Cancer
AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma
RATIONALE: Monoclonal antibodies, such as AMG-479, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Conditions
- Lymphoma, Prostate Cancer, Sarcoma, Small Intestine Cancer
- Trial name
- NCT00562380
- Testing
- ganitumab, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Amgen
Solid Tumor (Phase I), Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Phase 1a/1b Clinical Trials to Evaluate the Safety and Preliminary Efficacy of GNTbm-38.
This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of GNTbm-38 in adult patients with advanced solid tumors and R/R PTCL.
- Trial name
- NCT07842445
- Testing
- GNTbm-38
- Volunteers
- 70 people
- Sponsor
- Great Novel Therapeutics Biotech & Medicals Corporation
Lymphoma
Beta Alethine in Treating Patients With Low-Grade Lymphoma
RATIONALE: Biological therapies such as beta alethine use different ways to stimulate the immune system and stop cancer cells from growing.
- Trial name
- NCT00007839
- Testing
- beta alethine
- Where
- United States
- Sponsor
- LifeTime Pharmaceuticals
Persistent or Recurrent Cutaneous T-Cell Lymphoma
A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma
The purpose of this trial is to assess the efficacy of E7777 in participants with recurrent or persistent Cutaneous T-Cell Lymphoma (CTCL) in Stage I - III participants as assessed by objective response rate (ORR).
- Trial name
- NCT01871727
- Testing
- E7777 9 mcg/kg
- Where
- 22 sites in United States, Australia and 1 more
- Volunteers
- 112 people
- Sponsor
- Eisai Inc.
Relapsed or Refractory Non-Hodgkin Lymphoma
Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
This is a multi-center, non-randomized and open-label phase I/IIa clinical study to evaluate the safety, tolerability, and efficacy of ICP-490 in patients with relapsed or refractory non-hodgkin lymphoma.
- Trial name
- NCT06845241
- Testing
- ICP-490
- Where
- 6 sites in China
- Volunteers
- 68 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the cancer. PURPOSE: Phase I trial to study the effectiveness of VEGF Trap in treating patients who have relapsed or…
- Trial name
- NCT00045266
- Testing
- ziv-aflibercept
- Where
- United States
- Sponsor
- Regeneron Pharmaceuticals
Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral…
- Conditions
- Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma, Non-Hodgkin
- Trial name
- ON-5001 (NCT06022029)
- Testing
- ONM-501, Cemiplimab
- Where
- 16 sites in United States, Australia
- Volunteers
- 168 people
- Sponsor
- OncoNano Medicine, Inc.
Diffuse Large B Cell Lymphoma
Follow-up Study of SyB L-0501 in Combination With Rituximab to Treat DLBCL
This study is a follow-up study to update the survival time data (overall survival, progression-free survival, and duration of response) of the subjects who received SyB L-0501 at least once in Phase III Study of SyB L-0501 in…
- Trial name
- NCT04354402
- Testing
- No intervention
- Where
- 17 sites in Japan
- Volunteers
- 25 people
- Sponsor
- SymBio Pharmaceuticals